Press Releases

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David ...

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting2018-04-09T06:55:22-07:00

Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference

-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, ...

Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference2018-03-21T09:31:14-07:00

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH ...

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference2017-10-31T01:12:48-07:00

Forge therapeutics announces participation in upcoming scientific and industry events

San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and ...

Forge therapeutics announces participation in upcoming scientific and industry events2017-10-24T00:35:50-07:00

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas

- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships –  ...

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas2017-10-12T15:06:06-07:00

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., ...

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum2017-10-09T16:55:18-07:00

Forge Therapeutics to present at World Anti-Microbial Resistance Congress 2017

San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., (Forge) announced today that the company will present a talk entitled, “Forging new ...

Forge Therapeutics to present at World Anti-Microbial Resistance Congress 20172017-10-04T14:16:36-07:00

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data ...

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 20172017-10-06T18:31:58-07:00
Go to Top